Haematotoxicity from chemotherapy course 1 already observed?
 
No
Yes
Leukopenia:WHO=4 (<1)
(WBC*10³/mm³)WHO=3 (>=1 and <2)
 WHO=2 (>=2 and <3)
 WHO=1 (>=3 and <4)
 WHO=0 (>=4)
 missing
Thrombopenia:WHO=4 (<25)
(Platelets*10³/mm³)WHO=3 (>=25 and <50)
 WHO=2 (>=50 and <75)
 WHO=1 (>=75 and <100)
 WHO=0 (>=100)
 missing
Anaemia:WHO=4 (<6.5)
(Haemoglobin*g/dl)WHO=3 (>=6.5 and <8)
 WHO=2 (>=8 and <9.5)
 WHO=1 (>=9.5 and <11)
 WHO=0 (>=11)
 missing
Chemotherapy regimen
6 cyclesCHOP and 14-day intervals with G-CSF
6 cyclesCHOEPand 14-day intervals with G-CSF
6 cyclesCHOP and 21-day intervals withoutG-CSF
6 cyclesCHOEPand 21-day intervals withoutG-CSF
Factor
Age18-60 years61-75 years
Gendermalefemaleunknown
Overweight (body size cm)*  noyesunknown
Initial γGTγGT<=Upper Normal LimitγGT>Upper Normal Limitunknown
Ann Arbor stageI, IIIII, IVunknown
Bone marrow involvementnoyes and <=25%unknown
Initial LDHLDH<=Upper Normal LimitLDH>Upper Normal Limitunknown
Initial leucocyte count>7100x10³/mm³<=7100x10³/mm³unknown
Initial thrombocyte count>150x10³/mm³<=150x10³/mm³unknown
Initial haemoglobinfemale: >12; male: >13 g/dlfemale: <=12; male: <=13 g/dlunknown
Performance status ECOG0, 12, 3unknown
Vincristine (body surface area m²)#  <=1.05 mg/m²>1.05 mg/m²unknown
* The limit is calculated as 115% Broca-index (body size in cm - 100)
# With the body surface area information it is possible to decide whether the dose limit is exceeded (2 mg / body surface area > 1.05 mg/m²) or not
 
 
Show models LeukopeniaThrombopeniaAnaemia
Show expected toxicity forCycle 1-3Cycle 4-6both
Colour schemeMulticolouredBlue

Last modified 16/09/29 03:41 pm